Statistical versus clinical significance of the CURE study in acute coronary syndromes: Reply  by Khot, Umesh N & Nissen, Steven E
With respect to cost-effectiveness of clopidogrel in acute coro-
nary syndromes, data from the CURE study (6) show that the cost
per event avoided with clopidogrel in the study is comparable to
other cost-effective therapies in cardiovascular disease.
Strategies to prevent major cardiovascular events such as MI,
cardiovascular death, and stroke are clinically important. Preventing
two events per 100 people for nine months of therapy is comparable
to most other treatments in the prevention of cardiovascular events,
including aspirin, beta-blockers, angiotensin-converting enzyme in-
hibitors, and statins in patients following MI (7). Moreover, the
cumulative impact of these various strategies add up to a large benefit.
Therefore, we believe that CURE is not only statistically significant,
but also that the results are clinically relevant and important.
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REPLY
We appreciate the interest by Drs. Joyner and Flather in our
Viewpoint.
We did not intend to imply that troponin elevations alone were
sufficient to meet the end point of myocardial infarction (MI), but
rather that the addition of troponin to creatine kinase-MB fraction
(CK-MB) measurements would increase the number of events
counted as MI within the appropriate clinical context (chest
pain/electrocardiographic changes). Nevertheless, as noted in our
Viewpoint, we acknowledge that clopidogrel reduces nonfatal MI.
The definition of minor bleeding—“other hemorrhages that led
to interruption of the study medication” (1)—is considerably more
selective than that used in other similar clinical trials (2). Requiring
interruption of the study medication to achieve this end point will
dramatically reduce reported minor bleeding (3). Thus, it is
important to know the incidence of minor bleeding with clopi-
dogrel using conventional definitions.
The rate of procedures in Clopidogrel in Unstable angina to
prevent Recurrent Events (CURE), although similar to PURSUIT as
a whole, is markedly less than that for U.S. patients in PURSUIT
(catheterization 83%; percutaneous coronary intervention 35%; coro-
nary artery bypass graft surgery [CABG] 20%) (4). Furthermore, the
rate of revascularization during initial hospitalization is 55% in the
U.S. compared with only 22% in CURE. Thus, CURE reflects a
conservative management strategy not widely used in the U.S.
Citing an average time to surgery of 5.5 days in the U.S. from
TACTICS/TIMI-18, the CURE investigators contend that stop-
ping clopidogrel for five days prior to surgery would not delay the
performance of CABG. This, however, is misleading. For one,
they have chosen to cite the mean time to surgery from random-
ization rather than the median time. The mean time will, by its
nature, be skewed higher by outliers yielding a larger value for the
time to surgery. In contrast, the median time to surgery for all
patients in TACTICS/TIMI-18 was only 3.7 days from random-
ization; it is almost certainly less in the U.S. (5). Furthermore, the
most relevant time frame is the time from catheterization rather
than randomization, as the decision to withhold clopidogrel will
not occur until surgical anatomy is determined by cardiac cathe-
terization. With catheterization being performed a median of one
day after randomization, the CURE investigators are asking
cardiologists and surgeons to routinely delay CABG for an average
of six days after initial presentation. We find it very difficult to
rationalize a routine six-day waiting period in this high-risk
subgroup, who typically have severe left main and/or critical
multivessel coronary artery disease.
Although clopidogrel may be “cost-effective,” this does not
mean that it is without cost. Our simple calculations vividly
illustrate the billions of dollars that would be spent to achieve the
purported benefits of clopidogrel.
Finally, suggesting that clopidogrel is similar to aspirin, beta-
blockers, angiotensin-converting enzyme inhibitors, and statins
greatly overstates its benefit. These four therapies all clearly reduce
mortality; clopidogrel does not. Clopidogrel’s benefit is limited to
nonfatal MI, making it crucially important to account for clinically
significant end points such as major bleeding and strategic con-
cerns regarding early CABG. Accounting for these real risks leads
to the conclusion that routine administration of clopidogrel re-
mains unwarranted, particularly in centers practicing an early
revascularization strategy.
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